Sign Up Now to Download a Free Research Report on PPHM
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Peregrine Pharmaceuticals Inc.
Peregrine Pharmaceuticals shares traded in the range of $1.76 to $2.06 Monday on volume of nearly 19 million shares traded. The company announced that it has reached an agreement with the FDA on a Phase III registration trial design for bavituximab in second-line non-small cell lung cancer (NSCLC).
Going forward ... (see research report)
Subscribe to News Feeds